Clinical Trial

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

Name: Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL — clinical trial record (NCT07255963)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the efficacy of combining pirtobrutinib, lisaftoclax, and rituximab (PVR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy and to explore a more effective treatment strategy for this patient population.

Trial Details

NCT Number	NCT07255963
Lead Sponsor	The First Affiliated Hospital of Soochow University
Conditions	DLBCL - Diffuse Large B Cell Lymphoma
Enrollment	29 participants
Start Date	2025-11-30
Primary Completion	2028-09-30 (estimated)
Study Completion	2030-09-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-01